Literature DB >> 20385424

Cancer gene discovery in hepatocellular carcinoma.

Lars Zender1, Augusto Villanueva, Victoria Tovar, Daniela Sia, Derek Y Chiang, Josep M Llovet.   

Abstract

Hepatocellular carcinoma (HCC) is a deadly cancer, whose incidence is increasing worldwide. Albeit the main risk factors for HCC development have been clearly identified, such as hepatitis B and C virus infection and alcohol abuse, there is still preliminary understanding of the key drivers of this malignancy. Recent data suggest that genomic analysis of cirrhotic tissue - the pre-neoplastic carcinogenic field - may provide a read-out to identify at risk populations for cancer development. Given this contextual complexity, it is of utmost importance to characterize the molecular pathogenesis of this disease, and pinpoint the dominant pathways/drivers by integrative oncogenomic approaches and/or sophisticated experimental models. Identification of the dominant proliferative signals and key aberrations will allow for a more personalized therapy. Pathway-based approaches and functional experimental studies have aided in identifying the activation of different signaling cascades in HCC (e.g. epidermal growth factor, insulin-like growth factor, RAS, MTOR, WNT-betacatenin, etc.). However, the introduction of new high-throughput genomic technologies (e.g. microarrays, deep sequencing, etc.), and increased sophistication of computational biology (e.g. bioinformatics, biomodeling, etc.), opens the field to new strategies in oncogene and tumor suppressor discovery. These oncogenomic approaches are framed within emerging new disciplines such as systems biology, which integrates multiple inputs to explain cancer onset and progression. In addition, the consolidation of sophisticated animal models, such as mosaic cancer mouse models or the use of transposons for mutagenesis screens, have been instrumental for the identification of novel tumor drivers. We herein review some classical as well as some recent fast track approaches for oncogene discovery in HCC, and provide a comprehensive landscape of the currently known spectrum of molecular aberrations involved in hepatocarcinogenesis. Copyright 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20385424      PMCID: PMC2905725          DOI: 10.1016/j.jhep.2009.12.034

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  103 in total

Review 1.  Hepatocellular carcinoma pathogenesis: from genes to environment.

Authors:  Paraskevi A Farazi; Ronald A DePinho
Journal:  Nat Rev Cancer       Date:  2006-09       Impact factor: 60.716

Review 2.  Dysregulation of growth factor signaling in human hepatocellular carcinoma.

Authors:  K Breuhahn; T Longerich; P Schirmacher
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

Review 3.  The mighty mouse: genetically engineered mouse models in cancer drug development.

Authors:  Norman E Sharpless; Ronald A Depinho
Journal:  Nat Rev Drug Discov       Date:  2006-08-18       Impact factor: 84.694

Review 4.  mTOR and cancer: insights into a complex relationship.

Authors:  David M Sabatini
Journal:  Nat Rev Cancer       Date:  2006-08-17       Impact factor: 60.716

5.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.

Authors:  Sandrine Boyault; David S Rickman; Aurélien de Reyniès; Charles Balabaud; Sandra Rebouissou; Emmanuelle Jeannot; Aurélie Hérault; Jean Saric; Jacques Belghiti; Dominique Franco; Paulette Bioulac-Sage; Pierre Laurent-Puig; Jessica Zucman-Rossi
Journal:  Hepatology       Date:  2007-01       Impact factor: 17.425

6.  Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population.

Authors:  Shao Hui Tang; Dong Hua Yang; Wei Huang; Hong Ke Zhou; Xiao Hua Lu; Gang Ye
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

7.  Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.

Authors:  Pal Kaposi-Novak; Ju-Seog Lee; Luis Gòmez-Quiroz; Cédric Coulouarn; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Clin Invest       Date:  2006-05-18       Impact factor: 14.808

8.  Genomic progression in mouse models for liver tumors.

Authors:  A D Tward; K D Jones; S Yant; M A Kay; R Wang; J M Bishop
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2005

9.  Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors.

Authors:  L Zender; W Xue; C Cordón-Cardo; G J Hannon; R Lucito; S Powers; P Flemming; M S Spector; S W Lowe
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2005

10.  Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach.

Authors:  Lars Zender; Mona S Spector; Wen Xue; Peer Flemming; Carlos Cordon-Cardo; John Silke; Sheung-Tat Fan; John M Luk; Michael Wigler; Gregory J Hannon; David Mu; Robert Lucito; Scott Powers; Scott W Lowe
Journal:  Cell       Date:  2006-06-30       Impact factor: 41.582

View more
  69 in total

1.  Theranostic applications: Non-ionizing cellular and molecular imaging through innovative nanosystems for early diagnosis and therapy.

Authors:  Sergio Casciaro
Journal:  World J Radiol       Date:  2011-10-28

Review 2.  Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad.

Authors:  Kari Nichole Nejak-Bowen; Satdarshan P S Monga
Journal:  Semin Cancer Biol       Date:  2010-12-21       Impact factor: 15.707

Review 3.  Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma.

Authors:  Amir Shlomai; Ype P de Jong; Charles M Rice
Journal:  Semin Cancer Biol       Date:  2014-01-20       Impact factor: 15.707

4.  RNA editing enters the limelight in cancer.

Authors:  Angela Gallo
Journal:  Nat Med       Date:  2013-02       Impact factor: 53.440

5.  A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma.

Authors:  Paul C Schröder; Víctor Segura; José Ignacio Riezu; Bruno Sangro; José M Mato; Jesús Prieto; Enrique Santamaría; Fernando J Corrales
Journal:  Funct Integr Genomics       Date:  2011-05-12       Impact factor: 3.410

6.  β-catenin accumulation in nuclei of hepatocellular carcinoma cells up-regulates glutathione-s-transferase M3 mRNA.

Authors:  Yu-Sang Li; Min Liu; Yoshihiro Nakata; He-Bin Tang
Journal:  World J Gastroenterol       Date:  2011-04-07       Impact factor: 5.742

7.  Monoamine Oxidase B in Renal Cell Carcinoma.

Authors:  Ingrid Hodorová; Silvia Rybárová; Peter Solár; Marián Benický; Dušan Rybár; Zuzana Kováčová; Jozef Mihalik
Journal:  Med Sci Monit       Date:  2018-08-04

8.  Hepatocellular alterations and dysregulation of oncogenic pathways in the liver of transgenic mice overexpressing growth hormone.

Authors:  Johanna G Miquet; Thomas Freund; Carolina S Martinez; Lorena González; María E Díaz; Giannina P Micucci; Elsa Zotta; Ravneet K Boparai; Andrzej Bartke; Daniel Turyn; Ana I Sotelo
Journal:  Cell Cycle       Date:  2013-02-21       Impact factor: 4.534

Review 9.  Functional and genetic deconstruction of the cellular origin in liver cancer.

Authors:  Jens U Marquardt; Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Nat Rev Cancer       Date:  2015-11       Impact factor: 60.716

10.  Optimal surveillance program for hepatocellular carcinoma - getting ready, but not yet.

Authors:  Grace Lai-Hung Wong
Journal:  World J Hepatol       Date:  2015-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.